陕西麦科奥特医药科技股份有限公司

STARCOIN GROUP

AE LOGISTICS

GUANZE MEDICAL

WATER INDUSTRY

ZHONGSHI MINAN

IDT INT'L

HAIZHI TECH GP

MANY IDEA CLOUD

FIRST CAP GP

XL2CSOPCOIN-U

588250

512010

159859

513700

516500

588860

512290

<p>Everest Medicines Limited has secured an exclusive license from Shaanxi Micot Pharmaceutical Technology Co., Ltd. to commercialize MT1013 in Greater China and other Asian markets. MT1013 is a first-in-class dual-targeting receptor agonist polypeptide aimed at treating secondary hyperparathyroidism, with potential expansion into chronic kidney disease-mineral and bone disorder and osteoporosis. This collaboration will enhance Everest Medicines’ nephrology portfolio.</p>

Reuters

VanEck Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ALPS Medical Breakthrough

Tianhong CNI BIOMEDICINE ETF

Penghua CSI HK Connect Health Care Composite ETF

iShares Biotechnology ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

iShares US Pharma

Huaan Hang Seng Biotech ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng Health Care ETF(QDII)

Yinhua CNI HK Connect Innovative Drugs ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Invesco Biotechnology & Genome ETF

Guotai CSI Bio-medicine ETF

SPDR S&P Biotech

Everest Medicines Secures Exclusive License to Commercialize MT1013 in Greater China and Asia

陕西麦科奥特医药科技股份有限公司(N25261.HK)

Everest Medicines Secures Exclusive License to Commercialize MT1013 in Greater China and Asia